Share this article on:

SAFETY AND IMMUNOGENICITY OF LIVE VARICELLA VIRUS VACCINE IN CHILDREN WITH HUMAN IMMUNODEFICIENCY VIRUS TYPE 1

Armenian, Saro H. DO*‡; Han, Jin Young MD, PhD*‡; Dunaway, Theresa M. RN†‡; Church, Joseph A. MD†‡

The Pediatric Infectious Disease Journal: April 2006 - Volume 25 - Issue 4 - p 368-370
doi: 10.1097/01.inf.0000207492.97867.15
Brief Reports

Live varicella virus vaccine was administered to 10 stable human immunodeficiency virus type 1 (HIV-1)-infected children. Subjects were monitored for adverse reactions, HIV-1 plasma levels, CD4+ T cell counts and immune responses. The vaccine was well-tolerated. Varicella-zoster virus-specific lymphocyte proliferative responses were detected in all subjects by 4 weeks and in 9 of 10 subjects 1 year after vaccination.

From the Divisions of *General Pediatrics and †Clinical Immunology and Allergy, Childrens Hospital Los Angeles and ‡Keck School of Medicine, University of Southern California, Los Angeles, CA

Accepted for publication November 23, 2005.

Supported by NIH NCRR GCRC grant MO1 RR-43.

E-mail JChurch@chla.usc.edu. Reprints not available.

© 2006 Lippincott Williams & Wilkins, Inc.